SlideShare una empresa de Scribd logo
1 de 16
DIGOXIN TOXICITY
By Dr.VIJAY
Department of Pharmacology
DIGOXIN
 SOURCE:
 STRUCTURE:
 MECHANISM OF ACTION:
DIGOXIN TOXICITY
PREDISPOSING FACTORS:
 Age
 Hypokalemia
 Hypercalcemia
 Impaired renal function
 Cor pulmonale
 Cardiac status
 Hormones
 Inappropriate use
CAUSES :
 Drug interactions causing increase in digoxin
levels:
 Hypokalemia:
 Calcium salts:
 Drugs which displace digoxin from
protien binding sites:
 Catecholamines,Sch:
Manifestations of Toxicity
 CARDIAC TOXICITY:
Most common manifestation:
PAROXYSMAL ATRIAL
TACHYCARDIA WITH BLOCK
Others: Multifocal extrasystoles & bigeminy
AV block
Sinoatrial arrest
VT and VF
 GASTROINTESTINAL TOXICITY:
 NEUROLOGICAL TOXICITY:
 MISCELLANEOUS TOXICITY:skin
rash,eosinophilia,gynecomastia.
 TOXICITY in Pregnancy:
DIFFERENTIAL DIAGNOSIS
 CHF and Pulmonary edema
 Heart Block
 Beta blocker toxicity
 VT and VF
 Low K and high K level
 Low Mg and high Ca levels.
DIAGNOSIS
 Symptoms and signs:
 Past h/o digitalization:
 ECG:
 Electrolyte and Renal status:
 Plasma digoxin level:0.5-2ng/ml:
After acute ingestion digoxin level do not
necessarily correlate with toxicity.
T1/2 of digoxin is reduced to 10-12hrs after
acute ingestion.
 Plasma digoxin levels should be
measured at least 6 hours after the last
dose, since this is the time required for
attainment of the steady state.
 An extremely rapid radioimmunoassay for digoxin
on the use of iodine 125-labelled digoxin and of a gel
equilibration technique for the separation of antibody-
bound and free digoxin.
 Endogenous Digoxin Like
Immunoreactive Substances {DLIS}
seen in neonates,renal insufficiency,liver
disease,SAH,CHF,diabetes.
TREATMENT OF TOXICITY
 Stop digoxin and diuretics:
 GIT decontamination:
 Decreasing absorption:
 Estimate serum potassium:
 Bradycardia:
 Mild toxicity:
Potassium salts:5-7.5g of KCl
Serious arrhythmias:40mEq of KCl in 500ml
of 5% glucose IV OVER 2-4 hrs.
C/I to use of potassium:
 Supraventricular tachyarrhythmias:
Propranolol :oral dose of 10-40mg every
6hrs /IV .5-1-1mg.
 Ventricular tachycardia:
Lignocaine:1-2mg /kg IV repeat in 20-
30mins.
Phenytoin: IV:250mg well diluted over 3-
5min.
 Severe toxicity:DIGIBIND
Antidigoxin antibodies:
Source:
MOA:
Molecular weight:
T1/2:
Indications:
Life threatening arrhythmias
Hemodynamic instability
Severe bradycardia
Serum potassium level:
Plasma digoxin level:
Time taken for complete response:
 Dosing of Digibind:
Vials of digibind=digoxin level[ng/ml]x wt[kg]
100
1Vial of Digibind=40mg
= neutralizes 0.6mg of digoxin.
 Side effects of Digibind:
Allergic reactions
Exacerbation of CHF
Hypokalemia
Plasma digoxin level unreliable
after digibind is given.
Increased ventricular response
to atrial fibrillation and flutter.
 CONTRAINDICATIONS:Allergic to sheep
protien, papain, papaya extracts.

Más contenido relacionado

La actualidad más candente (20)

Ace inhibitor
Ace inhibitorAce inhibitor
Ace inhibitor
 
Alprazolam
Alprazolam Alprazolam
Alprazolam
 
Diazepam
DiazepamDiazepam
Diazepam
 
Digitalis nikku ppt
Digitalis nikku pptDigitalis nikku ppt
Digitalis nikku ppt
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
Management of asthma
Management of asthmaManagement of asthma
Management of asthma
 
Dopamine
DopamineDopamine
Dopamine
 
Angina pectoris
Angina pectorisAngina pectoris
Angina pectoris
 
Digitalis toxicity.pptx
Digitalis toxicity.pptxDigitalis toxicity.pptx
Digitalis toxicity.pptx
 
Pharmacology angina
Pharmacology   anginaPharmacology   angina
Pharmacology angina
 
Heparin
HeparinHeparin
Heparin
 
PHARMACOTHERAPY OF MYOCARDIAL INFARCTION
PHARMACOTHERAPY OF MYOCARDIAL INFARCTIONPHARMACOTHERAPY OF MYOCARDIAL INFARCTION
PHARMACOTHERAPY OF MYOCARDIAL INFARCTION
 
Dobutamine profile
Dobutamine profileDobutamine profile
Dobutamine profile
 
Antispasmodic drugs
Antispasmodic drugsAntispasmodic drugs
Antispasmodic drugs
 
Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
Asthma ppt
 Asthma ppt   Asthma ppt
Asthma ppt
 
Diuretics II
Diuretics IIDiuretics II
Diuretics II
 
Barbiturates
BarbituratesBarbiturates
Barbiturates
 
Amiodarone
AmiodaroneAmiodarone
Amiodarone
 
Digoxin Toxicity
Digoxin Toxicity Digoxin Toxicity
Digoxin Toxicity
 

Similar a Digitalis toxicity vijay

Diabetic emergencies
Diabetic emergenciesDiabetic emergencies
Diabetic emergenciesRichardKeshi
 
Endocrine hypertension
Endocrine hypertensionEndocrine hypertension
Endocrine hypertensionNaveen Kumar
 
CCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTURECCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTUREADAMAGABA
 
Congenital adrenal hyperplasia
Congenital  adrenal hyperplasiaCongenital  adrenal hyperplasia
Congenital adrenal hyperplasiaShiva Polisetty
 
Cardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecteCardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affectewajidullah9551
 
Endocrine disorders of adrenal gland
Endocrine disorders of adrenal glandEndocrine disorders of adrenal gland
Endocrine disorders of adrenal glandSubhasish Deb
 
Diabetic ketoacidosis
Diabetic ketoacidosisDiabetic ketoacidosis
Diabetic ketoacidosisSonam Yeshi
 
Diabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptxDiabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptxHafizuddinSalim1
 
MINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASEMINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASERaheel Ahmed
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
Approach to a child with jaundice
Approach to a child with jaundice Approach to a child with jaundice
Approach to a child with jaundice Bala Sankar
 
juvinile diabetes mellitus clinical features and investigations
 juvinile diabetes mellitus clinical features and investigations juvinile diabetes mellitus clinical features and investigations
juvinile diabetes mellitus clinical features and investigationsShiva Polisetty
 
Endocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney diseaseEndocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney diseaseDr. Lala Shourav Das
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementMedicineAndFamily
 
Nephrotic syndrome final
Nephrotic syndrome finalNephrotic syndrome final
Nephrotic syndrome finalakilav99
 

Similar a Digitalis toxicity vijay (20)

Diabetic emergencies
Diabetic emergenciesDiabetic emergencies
Diabetic emergencies
 
Seco dka
Seco dkaSeco dka
Seco dka
 
Endocrine hypertension
Endocrine hypertensionEndocrine hypertension
Endocrine hypertension
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
CCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTURECCF PHARMACOLOGY. PRESENTED BY A LECTURE
CCF PHARMACOLOGY. PRESENTED BY A LECTURE
 
Congenital adrenal hyperplasia
Congenital  adrenal hyperplasiaCongenital  adrenal hyperplasia
Congenital adrenal hyperplasia
 
Cardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecteCardiac Glycosides and it's side affecte
Cardiac Glycosides and it's side affecte
 
Endocrine disorders of adrenal gland
Endocrine disorders of adrenal glandEndocrine disorders of adrenal gland
Endocrine disorders of adrenal gland
 
Diabetic ketoacidosis
Diabetic ketoacidosisDiabetic ketoacidosis
Diabetic ketoacidosis
 
Adrenocortical disorders
Adrenocortical disordersAdrenocortical disorders
Adrenocortical disorders
 
Diabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptxDiabetic Ketoacidosis.pptx
Diabetic Ketoacidosis.pptx
 
Digoxin
DigoxinDigoxin
Digoxin
 
MINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASEMINIMAL CHANGE DISEASE
MINIMAL CHANGE DISEASE
 
43651
4365143651
43651
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
Approach to a child with jaundice
Approach to a child with jaundice Approach to a child with jaundice
Approach to a child with jaundice
 
juvinile diabetes mellitus clinical features and investigations
 juvinile diabetes mellitus clinical features and investigations juvinile diabetes mellitus clinical features and investigations
juvinile diabetes mellitus clinical features and investigations
 
Endocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney diseaseEndocrine disorders in chronic kidney disease
Endocrine disorders in chronic kidney disease
 
Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
 
Nephrotic syndrome final
Nephrotic syndrome finalNephrotic syndrome final
Nephrotic syndrome final
 

Más de yerroju vijay

IA-English-Life QP.pdf
IA-English-Life QP.pdfIA-English-Life QP.pdf
IA-English-Life QP.pdfyerroju vijay
 
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...yerroju vijay
 
Vegf inhibitors for ophthalmic use
Vegf inhibitors  for ophthalmic useVegf inhibitors  for ophthalmic use
Vegf inhibitors for ophthalmic useyerroju vijay
 
TYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSTYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSyerroju vijay
 

Más de yerroju vijay (6)

IA-English-Life QP.pdf
IA-English-Life QP.pdfIA-English-Life QP.pdf
IA-English-Life QP.pdf
 
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
 
Vegf inhibitors for ophthalmic use
Vegf inhibitors  for ophthalmic useVegf inhibitors  for ophthalmic use
Vegf inhibitors for ophthalmic use
 
Torsades de-pointes
Torsades de-pointesTorsades de-pointes
Torsades de-pointes
 
TYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORSTYROSINE KINASE INHIBITORS
TYROSINE KINASE INHIBITORS
 
Stem cell therapy
Stem cell therapyStem cell therapy
Stem cell therapy
 

Último

1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfAyushMahapatra5
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docxPoojaSen20
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterMateoGardella
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Shubhangi Sonawane
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingTeacherCyreneCayanan
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.MateoGardella
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 

Último (20)

1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 

Digitalis toxicity vijay

  • 3.
  • 4.
  • 5. DIGOXIN TOXICITY PREDISPOSING FACTORS:  Age  Hypokalemia  Hypercalcemia  Impaired renal function  Cor pulmonale  Cardiac status  Hormones  Inappropriate use CAUSES :
  • 6.  Drug interactions causing increase in digoxin levels:  Hypokalemia:  Calcium salts:  Drugs which displace digoxin from protien binding sites:  Catecholamines,Sch:
  • 7. Manifestations of Toxicity  CARDIAC TOXICITY: Most common manifestation: PAROXYSMAL ATRIAL TACHYCARDIA WITH BLOCK Others: Multifocal extrasystoles & bigeminy AV block Sinoatrial arrest VT and VF
  • 8.  GASTROINTESTINAL TOXICITY:  NEUROLOGICAL TOXICITY:  MISCELLANEOUS TOXICITY:skin rash,eosinophilia,gynecomastia.  TOXICITY in Pregnancy:
  • 9. DIFFERENTIAL DIAGNOSIS  CHF and Pulmonary edema  Heart Block  Beta blocker toxicity  VT and VF  Low K and high K level  Low Mg and high Ca levels.
  • 10. DIAGNOSIS  Symptoms and signs:  Past h/o digitalization:  ECG:  Electrolyte and Renal status:  Plasma digoxin level:0.5-2ng/ml: After acute ingestion digoxin level do not necessarily correlate with toxicity. T1/2 of digoxin is reduced to 10-12hrs after acute ingestion.
  • 11.  Plasma digoxin levels should be measured at least 6 hours after the last dose, since this is the time required for attainment of the steady state.  An extremely rapid radioimmunoassay for digoxin on the use of iodine 125-labelled digoxin and of a gel equilibration technique for the separation of antibody- bound and free digoxin.  Endogenous Digoxin Like Immunoreactive Substances {DLIS} seen in neonates,renal insufficiency,liver disease,SAH,CHF,diabetes.
  • 12. TREATMENT OF TOXICITY  Stop digoxin and diuretics:  GIT decontamination:  Decreasing absorption:  Estimate serum potassium:  Bradycardia:  Mild toxicity: Potassium salts:5-7.5g of KCl Serious arrhythmias:40mEq of KCl in 500ml of 5% glucose IV OVER 2-4 hrs. C/I to use of potassium:
  • 13.  Supraventricular tachyarrhythmias: Propranolol :oral dose of 10-40mg every 6hrs /IV .5-1-1mg.  Ventricular tachycardia: Lignocaine:1-2mg /kg IV repeat in 20- 30mins. Phenytoin: IV:250mg well diluted over 3- 5min.
  • 14.  Severe toxicity:DIGIBIND Antidigoxin antibodies: Source: MOA: Molecular weight: T1/2: Indications: Life threatening arrhythmias Hemodynamic instability Severe bradycardia Serum potassium level: Plasma digoxin level: Time taken for complete response:
  • 15.  Dosing of Digibind: Vials of digibind=digoxin level[ng/ml]x wt[kg] 100 1Vial of Digibind=40mg = neutralizes 0.6mg of digoxin.
  • 16.  Side effects of Digibind: Allergic reactions Exacerbation of CHF Hypokalemia Plasma digoxin level unreliable after digibind is given. Increased ventricular response to atrial fibrillation and flutter.  CONTRAINDICATIONS:Allergic to sheep protien, papain, papaya extracts.